28.86
+1.1(+3.96%)
Currency In USD
| Previous Close | 27.76 |
| Open | 28.25 |
| Day High | 28.95 |
| Day Low | 27.83 |
| 52-Week High | 46.48 |
| 52-Week Low | 25.28 |
| Volume | 1.62M |
| Average Volume | 1.95M |
| Market Cap | 4.58B |
| PE | 10.42 |
| EPS | 2.77 |
| Moving Average 50 Days | 30.49 |
| Moving Average 200 Days | 33.44 |
| Change | 1.1 |
If you invested $1000 in TG Therapeutics, Inc. (TGTX) 10 years ago, it would be worth $3,571.78 as of February 08, 2026 at a share price of $28.86. Whereas If you bought $1000 worth of TG Therapeutics, Inc. (TGTX) shares 5 years ago, it would be worth $550.45 as of February 08, 2026 at a share price of $28.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
GlobeNewswire Inc.
5 hours ago
Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS A Media Snippet accompanying this announcement is available by clicking on this link. N
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
GlobeNewswire Inc.
Feb 06, 2026 12:30 PM GMT
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sc
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
GlobeNewswire Inc.
Jan 13, 2026 9:25 PM GMT
Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectivelyFull Year 2026 target total globa